Magdalena Ślusarczyk

Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development

Magdalena Ślusarczyk, Monica Huerta Lopez, Jan Balzarini et al. · Journal of Medicinal Chemistry · 2014 · 151 citations

Medicine, Oncology, Pharmacology +16

Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside

Christopher McGuigan, Paola G. S. Murziani, Magdalena Ślusarczyk et al. · Journal of Medicinal Chemistry · 2011 · 117 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2′-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes

Johan Vande Voorde, Sandra Liekens, Christopher McGuigan et al. · Biochemical Pharmacology · 2011 · 41 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +8

Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides

Christopher McGuigan, Claire Bourdin, Marco Derudas et al. · European Journal of Medicinal Chemistry · 2013 · 32 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Synthesis of Phosphoramidate Prodrugs: ProTide Approach

Michaela Serpi, Karolina Madela, Fabrizio Pertusati et al. · Current Protocols in Nucleic Acid Chemistry · 2013 · 27 citations

Pharmacy, Medicinal Chemistry, Pharmacology +11